Skip to main content Skip to main navigation menu Skip to site footer

Clostridium difficile virulence factors as the cause of antibiotic-associated diarrhea (AAD): a literature review

Abstract

Clostridium difficile is an anaerobic gram-positive bacillus, capable of forming spores and toxins, transmitted to humans by the faecal-oral route C. difficile infection (CDI) is recognized as a typical cause of healthcare-associated infections (HAIs) and contributes to a significant proportion of morbidity and mortality of hospitalized patients. C. difficile culture and toxin examinations are still minimal in many hospitals in various Asian countries. As a result, reports of C. difficile in Asia are still rare, while reports of cases of CDI in Indonesia are still rare. Several risk factors including advanced age, antibiotic exposure, and hospitalization are strongly associated with CDI. C. difficile has the ability to colonize the large intestine, then release exotoxin proteins (TcdA, TcdB) causing colitis in people with risk factors. A diagnosis of suspected C. difficile infection in a patient with diarrhea without a clear alternative explanation, with relevant risk factors (including long antibiotic consumption, hospitalization events, and elderly age), was then performed microbiological examination to carry out proper management and control of infection. This study aims to review C. difficile virulence factors as the cause of antibiotic-associated diarrhea.

References

  1. Schäffler H, Breitrück A. Clostridium difficile - From colonization to infection. Vol. 9, Frontiers in Microbiology. Frontiers Media S.A.; 2018.
  2. Saito R, Usui Y, Ayibieke A, Nakajima J, Prah I, Sonobe K, et al. Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan. Gut Pathogens. 2019 Nov 4;11(1).
  3. Riley T v., Collins DA, Karunakaran R, Kahar MA, Adnan A, Hassan SA, et al. High prevalence of toxigenic and nontoxigenic clostridium difficile strains in Malaysia. Journal of Clinical Microbiology. 2018 Jun 1;56(6).
  4. Chrisnanda RH, Wardhani P. The incidence of Clostridium Difficile infection in diarrhea patients after receiving antibiotics at Dr. Soetomo Hospital Surabaya. Bali Medical Journal. 2019 Aug 1;8(2):434.
  5. Collins DA, Gasem MH, Habibie TH, Arinton IG, Hendriyanto P, Hartana AP, et al. Prevalence and molecular epidemiology of Clostridium difficile infection in Indonesia. New Microbes and New Infections. 2017 Jul 1;18:34–7.
  6. Collins DA, Riley T v. Clostridium difficile in Asia: Opportunities for one health management. Vol. 4, Tropical Medicine and Infectious Disease. MDPI AG; 2019.
  7. Shaw HA, Preston MD, Vendrik KEW, Cairns MD, Browne HP, Stabler RA, et al. The recent emergence of a highly related virulent Clostridium difficile clade with unique characteristics. Clinical Microbiology and Infection. 2020 Apr 1;26(4):492–8.
  8. Collins DA, Hawkey PM, Riley T v. Epidemiology of Clostridium difficile infection in Asia. Vol. 2, Antimicrobial Resistance and Infection Control. BioMed Central Ltd.; 2013.
  9. Collins D. Clostridium difficile infection in South-East Asia Features extraction for classification of endoscopic images View project Environmental and animal reservoirs of Clostridium difficile in Western Australia View project [Internet]. 2016. Available from: https://www.researchgate.net/publication/314117159
  10. Burke KE, Lamont JT. Clostridium difficile infection: A worldwide disease. Vol. 8, Gut and Liver. 2014. p. 1–6.
  11. Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: A systematic review and meta-analysis. Journal of Global Health. 2019;9(1).
  12. Rodriguez-Palacios A, Mo KQ, Shah BU, Msuya J, Bijedic N, Deshpande A, et al. Global and historical distribution of clostridioides difficile in the human diet (1981–2019): Systematic review and meta-analysis of 21886 samples reveal sources of heterogeneity, high-risk foods, and unexpected higher prevalence toward the tropic. Vol. 7, Frontiers in Medicine. Frontiers Media S.A.; 2020.
  13. Davies K, Lawrence J, Berry C, Davis G, Yu H, Cai B, et al. Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Frontiers in Public Health. 2020 Jul 17;8.
  14. Miranda-Katz M, Parmar D, Dang R, Alabaster A, Greenhow TL. Epidemiology and Risk Factors for Community Associated Clostridioides difficile in Children. In: Journal of Pediatrics. Mosby Inc.; 2020. p. 99–106.
  15. Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - An overview of the evidence base and challenges in data synthesis. Journal of Global Health. 2017 Jun 4;7(1).
  16. Cui Y, Dong D, Zhang L, Wang D, Jiang C, Ni Q, et al. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infectious Diseases. 2019 Nov 11;19(1).
  17. Cookson B. Hypervirulent strains of Clostridium difficile. Vol. 83, Postgraduate Medical Journal. 2007. p. 291–5.
  18. Fatima R, Aziz M. The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview. Cureus. 2019 Jan 29;
  19. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. Journal of Medical Microbiology. 2012 Jan;61(1):49–56.
  20. Yakob L, Riley T v., Paterson DL, Marquess J, Magalhaes RJS, Furuya-Kanamori L, et al. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: An epidemiological model. Scientific Reports. 2015 Jul 28;5.
  21. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. Journal of Bacteriology. 2010 Oct;192(19):4904–11.
  22. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases. 2008 Nov 1;47(9):1162–70.
  23. Muñoz M, Camargo M, Ríos-Chaparro DI, Gómez P, Patarroyo MA, Ramírez JD. Community-acquired infection with hypervirulent Clostridium difficile isolates that carry different toxin and antibiotic resistance loci: A case report. Gut Pathogens. 2017 Nov 9;9(1).
  24. Merrigan MM. Loyola eCommons Loyola eCommons Hypervirulent Clostridium Difficile Strains: Adherence, Toxin Hypervirulent Clostridium Difficile Strains: Adherence, Toxin Production and Sporulation Production and Sporulation [Internet]. 2010. Available from: https://ecommons.luc.edu/luc_diss/178
  25. Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, et al. Incidence and Outcomes Associated with Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(1).
  26. Vindigni SM, Surawicz CM. C. Difficile infection: Changing epidemiology and management paradigms. Vol. 6, Clinical and Translational Gastroenterology. Nature Publishing Group; 2015.
  27. Bouza E, Muñoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clinical Microbiology and Infection, Supplement. 2005;11(4):57–64.
  28. Davies K, Lawrence J, Berry C, Davis G, Yu H, Cai B, et al. Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Frontiers in Public Health. 2020 Jul 17;8.
  29. Tay HL, Chow A, Ng TM, Lye DC. Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore. Scientific Reports. 2019 Dec 1;9(1).
  30. Guh AY, Adkins SH, Li Q, Bulens SN, Farley MM, Smith Z, et al. Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study. Open Forum Infectious Diseases. 2017;4(4).
  31. Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - An overview of the evidence base and challenges in data synthesis. Journal of Global Health. 2017 Jun 4;7(1).
  32. Kamuju V, Kumar S, Khan WH, Vivekanandan P. Hypervirulent clostridium difficile ribotypes are cpg depleted. Vol. 9, Virulence. Taylor and Francis Inc.; 2018. p. 1422–5.
  33. Thornton CS, Rubin JE, Greninger AL, Peirano G, Chiu CY, Pillai DR. Epidemiological and genomic characterization of community-acquired Clostridium difficile infections. BMC Infectious Diseases. 2018 Aug 31;18(1).
  34. Gupta A, Khanna S. Community-acquired clostridium difficile infection: An increasing public health threat. Vol. 7, Infection and Drug Resistance. 2014. p. 63–72.
  35. al Assaad R, Dakessian A, Bachir R, Bizri AR, el Sayed M. Significance of Clostridium difficile in community-acquired diarrhea in a tertiary care center in Lebanon. Scientific Reports. 2020 Dec 1;10(1).
  36. Moore LSP. Article in Clinical Pharmacist [Internet]. 2012. Available from: https://www.researchgate.net/publication/232048140
  37. Oka K, Osaki T, Hanawa T, Kurata S, Okazaki M, Manzoku T, et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. Journal of Clinical Microbiology. 2012 Mar;50(3):915–21.
  38. Geoghegan O, Eades C, Moore LSP, Gilchrist M. Clostridium difficile: Diagnosis and treatment update. Clinical Pharmacist. 2017 Feb 1;9(2).
  39. Edwards AN, Suárez JM, McBride SM. Culturing and maintaining Clostridium difficile in an anaerobic environment. J Vis Exp. 2013;(79).
  40. Piacenti FJ, Leuthner KD. Antimicrobial stewardship and Clostridium difficile-associated diarrhea. Journal of Pharmacy Practice. 2013 Oct;26(5):506–13.
  41. Curcio Alejandro Cané Francisco Andrés Fernández Jorge Correa D. Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis. Infectious Diseases and Therapy [Internet]. 8. Available from: https://doi.org/10.6084/
  42. Curry S. Clostridium difficile. Vol. 30, Clinics in Laboratory Medicine. 2010. p. 329–42.
  43. Miura M, Kato H, Matsushita O. Identification of a novel virulence factor in Clostridium Difficile that modulates toxin sensitivity of cultured epithelial cells. Infection and Immunity. 2011 Sep;79(9):3810–20.
  44. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clinical Microbiology and Infection. 2001;7(8):421–7.
  45. Chen S, Sun C, Wang H, Wang J. The role of Rho GTPases in toxicity of Clostridium difficile toxins. Vol. 7, Toxins. MDPI AG; 2015. p. 5254–67.
  46. di Bella S, Ascenzi P, Siarakas S, Petrosillo N, di Masi A. Clostridium difficile toxins A and B: Insights into pathogenic properties and extraintestinal effects. Vol. 8, Toxins. MDPI AG; 2016.
  47. Janoir C. Virulence factors of Clostridium difficile and their role during infection. Anaerobe. 2016 Feb 1;37:13–24.
  48. Lyras D, O’Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009 Apr 30;458(7242):1176–9.
  49. Tijerina-Rodríguez L, Villarreal-Treviño L, Morfín-Otero R, Camacho-Ortíz A, Garza-González E. Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections. Vol. 2019, Canadian Journal of Infectious Diseases and Medical Microbiology. Hindawi Limited; 2019.

How to Cite

Wedari, N. L. P. H. ., Budayanti, N. N. S., & Darwinata, A. E. (2022). Clostridium difficile virulence factors as the cause of antibiotic-associated diarrhea (AAD): a literature review. Bali Medical Journal, 11(3), 1277–1281. https://doi.org/10.15562/bmj.v11i3.3696

HTML
5

Total
2

Share

Search Panel

Ni Luh Putu Harta Wedari
Google Scholar
Pubmed
BMJ Journal


Ni Nyoman Sri Budayanti
Google Scholar
Pubmed
BMJ Journal


Agus Eka Darwinata
Google Scholar
Pubmed
BMJ Journal